Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance
Michael S. Dahabieh, Fan Huang, Christophe Gonçalves, Raúl Ernesto Flores González, Sathyen A. Prabhu, Alicia M. Bolt, Erminia Di Pietro, Elie Khoury, John A. Heath, Ziyi Xu, Joelle Rémy-Sarrazin, Koren K. Mann, Alexandre Orthwein, François‐Michel Boisvert, Nancy Braverman, Wilson H. Miller, Sonia V. del Rincón
Abstract
ABCD3/PMP70: ATP binding cassette subfamily D member 3; ACOX1: acyl-CoA oxidase 1; AP: autophagosome; COX: cytochrome c oxidase; CQ: chloroquine; CRISPRi: clustered regularly interspaced short palindromic repeats interference; DLBCL: diffuse large B-cell lymphoma; GO: gene ontology; dCas9: Cas9 endonuclease dead, or dead Cas9; HDACi: histone deacetylase inhibitors; IHC: Immunohistochemistry; LAMP2: lysosomal associated membrane protein 2; LCFAs: long-chain fatty acids; LFQ-MS: label-free quantitation mass spectrometry; LPC: lysophoshatidylcholine; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MTOR: mechanistic target of rapamycin kinase; PBD: peroxisome biogenesis disorders; PTS1: peroxisomal targeting signal 1; ROS: reactive oxygen species; sgRNA: single guide RNA; VLCFAs: very-long chain fatty acids; Vor: vorinostat; WO: wash-off.